



02-04-08

EPW

Express Mail No. EB 132595207 US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of:	Jerussi <i>et al.</i>	Confirmation No.:	4423
Serial No.:	10/720,134	Art Unit:	1621
Filed:	November 25, 2003	Examiner:	Paul A. Zucker
For:	DERIVATIVES OF VENLAFAXINE AND METHODS OF PREPARING AND USING THE SAME	Attorney Docket No: (CAM:	4821-531-999 208423-999528)

**REQUEST FOR CORRECTED RECEIPT DATE**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

On November 5, 2007 a Response to Non-Final Office Action and Petition for Extension of Time (hereinafter "the Response") were mailed via express mail to the Commissioner for Patents in connection with the above-referenced U.S. patent application. However, the PTO receipt date for the Response is stamped November 6, 2007 (a copy of which is enclosed). In accordance with 37 CFR § 1.10(b), the Response was deposited directly with the United States Postal Service and accorded a clearly marked "date-in" of November 5, 2007. The date-stamped express mail receipt for express mail No. EB 132603053 US, which corresponds to the express mail number listed on the Response, is also enclosed.

As such, pursuant to 37 CFR § 1.10(c) and § 1.6(a)(2), Applicants hereby petition the Director to accord the Response a filing date of November 5, 2007, which is both the date of the Response and the "date-in" on the express mail receipt.


In Addition, Applicants paid for a one month extension of time for response. No additional fees are believed to have been charged in this matter, however if any extension

of time fee in excess of one month were inadvertently charged to Deposit Account No. 50-3013 in connection with the November 5, 2007 Response, the Commissioner is hereby authorized to credit such overpayment to Deposit Account No. 50-3013.

Respectfully submitted,

Date: February 1, 2008

for:

  
Hoon Choi

Anthony M. Insogna

**JONES DAY**


222 East 41st Street

New York, New York 10017-6702

(212) 326-3939

Ltd. Reg. No.: L0209

Reg. No.: 35,203



Express Mail No. EB 132603053 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Jerussi *et al.* Confirmation No.: 4423  
Serial No.: 10/720,134 Art Unit: 1621  
Filed: November 25, 2003 Examiner: Paul A. Zucker  
For: DERIVATIVES OF VENLAFAXINE AND METHODS OF PREPARING AND USING THE SAME Attorney Docket No: 4821-531-999  
CAM: 208423-999528

PETITION FOR EXTENSION OF TIME

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

It is respectfully requested that the time for filing a response to the Office Action mailed July 5, 2007 be extended for a period of one month from October 5, 2007 to and including November 5, 2007.

The fee for this extension is estimated to be \$120.00. Please charge the required fee to Jones Day Deposit Account No. 503013. A copy of this sheet is enclosed.

Respectfully submitted,

Date: November 5, 2007


for:

Hoon Choi  
Anthony M. Insogna  
**JONES DAY**  
12265 El Camino Real, Suite 200  
San Diego, CA 92130  
(858) 314-1200  
Ltd. Recog. No.: L0209  
Reg. No.: 35,203

Enclosure

11/06/2007 RFEKADU1 00000010 503013 10720134

01 FC:1251 120.00 DA



11-07-07

TFW

Express Mail No. EB 132603053 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Jerussi <i>et al.</i>	Confirmation No.:	4423
Serial No.:	10/720,134	Art Unit:	1621
Filed:	November 25, 2003	Examiner:	Paul A. Zucker
For:	DERIVATIVES OF VENLAFAXINE AND METHODS OF PREPARING AND USING THE SAME	Attorney Docket No:	4821-531-999
		CAM:	208423-999528

**RESPONSE PURSUANT TO 37 C.F.R. § 1.111**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the Non-Final Office Action mailed July 5, 2007, Applicants submit the following remarks for the consideration by the Examiner and entry into the record of the above-captioned application. Also submitted herewith is a Petition for Extension of Time, with provision for the required fee.

**Amendments to the Claims** are reflected in the listing of the claims that begins on page 2 of this paper.

**Remarks** begin on page 4 of this paper.

**AMENDMENTS TO THE CLAIMS**

The listing of claims will replace all prior versions, and listings, of claims in the application.

Claims 1-59. (Canceled).

60. (Previously Presented) A compound which is O-desmethylvenlafaxine succinate.

61. (Previously Presented) The compound of claim 60, wherein the compound is a hydrate of O-desmethylvenlafaxine succinate.

62. (Previously Presented) The compound of claim 61 which is O-desmethylvenlafaxine succinate monohydrate.

63. (Previously Presented) A pharmaceutical composition comprising a therapeutically effective amount of O-desmethylvenlafaxine succinate and a pharmaceutically acceptable carrier or excipient.

64. (Previously Presented) A pharmaceutical dosage form comprising a therapeutically effective amount of O-desmethylvenlafaxine succinate and a pharmaceutically acceptable carrier or excipient.

65. (Previously Presented) An oral dosage form comprising a therapeutically effective amount of O-desmethylvenlafaxine succinate and a pharmaceutically acceptable carrier or excipient.

66. (Previously Presented) The oral dosage form of claim 65, wherein the dosage form is a tablet or capsule.

67. (Previously Presented) The oral dosage form of claim 65, wherein the dosage form is a sustained release formulation.

68. (Previously Presented) The oral dosage form of claim 65, further comprising a rate controlling polymer material.

69. (Currently Amended) The oral dosage form of claim 68, wherein the rate controlling polymer is ~~hydropropylmethyl~~ hydroxypropylmethyl cellulose.

70. (Previously Presented) The oral dosage form of claim 65, wherein the oral dosage form further comprises a binder.

71. (Previously Presented) The oral dosage form of claim 70, wherein the binder is microcrystalline cellulose.

72-78. (Canceled).

### **REMARKS**

Claims 60-71 are pending in this application. Pursuant to a restriction requirement, claims 72-78 are canceled without prejudice to Applicants' right to pursue the subject matter recited by them in one or more divisional, continuation, or continuation-in-part applications. Claim 69 is amended to correct a typographical error. No new matter has been introduced.

At the outset, Applicants respectfully invite the Examiner's attention to the fact that claims 60-71 define the same patentable invention as claimed in U.S. Patent No. 6,673,838 B2, which issued to Hadfield *et al.* on January 6, 2004. Applicants note that the claims of Patent No. 6,673,838 B2 were allowed over U.S. Patent No. 4,535,186, which forms the basis for the two obviousness rejections of the outstanding Office Action.

#### **I. The Rejection Under 35 U.S.C. §103 Should be Withdrawn**

In the Office Action, claims 60-66 and 70 are rejected as allegedly obvious over Patent No. 4,535,186 to Husbands *et al.* ("Husbands"). (Office Action, page 2). Further, claims 67-69 and 71 are rejected as allegedly obvious over Husbands in view of U.S. Patent No. 6,274,171 to Sherman *et al.* ("Sherman"). (*Id.*, page 4). Applicants respectfully traverse each of these rejections.

Even assuming, *arguendo*, that a *prima facie* case of obviousness were established, Applicants respectfully submit that any presumption of obviousness is rebutted for at least the following reasons.

Applicants respectfully invite the Examiner's attention to U.S. Patent No. 6,673,838 B2 to Hadfield *et al.* ("Hadfield"), which discloses unexpectedly improved properties of the succinic salt. In particular, Hadfield discloses that "[t]he results of the site-specific intestinal absorption of ODV [O-desmethylvenlafaxine] succinate and ODV fumarate show that ODV succinate has better absorption in the small intestine and in the colon than ODV fumarate." (Hadfield, Example 13, columns 24-26 and Figure 13). Specifically, Hadfield discloses that the rat intestinal permeability coefficients (" $P_{eff}$ ") of the succinic salt are 0.912, 1.73, and 0.062<sup>1</sup> for the jejunum, ileum, and colon, respectively. (*Id.*). In contrast, the reported  $P_{eff}$  values of the fumarate salt for the jejunum, ileum, and colon are 0.245, 0.678, and 0, respectively. (*Id.*). Based on the disclosed experimental  $P_{eff}$  values, Hadfield discloses that

---

<sup>1</sup> 10<sup>-5</sup> cm/sec.  
LAI-2904456v1

while “the human *in vivo* Fa<sup>2</sup> of ODV succinate was predicted to be in the range of 60-77% in the small intestine and a Fa of 20% in the colon,” the “*in vivo* Fa of ODV fumarate was estimated to be in the range of 33-45% in the small intestine and 0 in the colon, indicating [an] overall low absorption of this compound in the entire GI tract.” (*Id.*) (emphasis added).

Consequently, Hadfield clearly discloses that the succinic salt of O-desmethylvenlafaxine is unexpectedly more advantageous than its fumarate salt. In view of these results, Applicants respectfully submit that any presumption of obviousness is rebutted, and thus, request that the rejection of claims 60-66 and 70 be withdrawn.

Second, with regard to claims 67-69 and 71, the Examiner alleges that these claims are “unpatentable over Husbands as applied to claims 60-66 and 70...and further in view of Sherman.” (Office Action, page 4). Specifically, the Examiner alleges that Sherman “teaches extended release formulations of venlafaxine hydrochloride[,]...extended release formulations of venlafaxine and microcrystalline cellulose” and “coatings of hydroxypropylmethyl cellulose.” (*Id.*). Regardless of the truth of this assertion, Applicants respectfully submit that claims 67-69 and 71, all of which depend ultimately from claim 65, are not obvious for at least the same reasons discussed above for claims 60-66.

## **II. Claim Objections**

On page 5 of the Office Action, claim 69 is objected to because “[t]he word hydroxypropylmethylcellulose is misspelled.” In this regard, claim 69 is amended to provide the correct spelling. Thus, Applicants respectfully request that the objection to claim 69 be withdrawn.

## **III. Conclusion**

For at least the foregoing reasons, Applicants respectfully submit that all of the pending claims are allowable, and thus, request that their rejections be withdrawn.

---

<sup>2</sup> Fa = human fraction of dose absorbed.  
LAI-2904456v1




No fee is believed due for the submission of this paper. However, if any fees are due for the submission of this paper or to avoid abandonment of this application, please charge them to Deposit Account No. 50-3013.

Respectfully submitted,

Date: November 5, 2007

for:

  
Hoon Choi

Anthony M. Insogna

**JONES DAY**

12265 El Camino Real, Suite 200

San Diego, CA 92130

(858) 314-1200

Ltd. Recog. No.: L0209

Reg. No.: 35,203



EB 132603053 US

**MAIL**

UNITED STATES POSTAL SERVICE®

Post Office To Addressee

**ORIGIN (POSTAL SERVICE USE ONLY)**

PO ZIP Code 92110	Day of Delivery <input type="checkbox"/> Next <input type="checkbox"/> 2nd <input type="checkbox"/> 3rd Del. Day	Postage \$ 21.40
Date Accepted 11/5/07	Scheduled Date of Delivery Monthly 1 - 3	Return Receipt Fee \$
Time Accepted 1:13 PM	Scheduled Time of Delivery <input type="checkbox"/> Noon <input type="checkbox"/> 3 PM	COD Fee \$
Int Rate <input type="checkbox"/> or Weight 1 lbs. 14 ozs.	Military <input type="checkbox"/> 2nd Day <input type="checkbox"/> 3rd Day	Insurance Fee \$
	Int'l Alpha Country Code	Total Postage & Fees \$ 21.40
		Acceptance Emp. Initials [Signature]

**DELIVERY (POSTAL USE ONLY)**

Delivery Attempt	Time	<input type="checkbox"/>
Mo. Day		
Delivery Attempt	Time	<input type="checkbox"/>
Mo. Day		
Delivery Date	Time	<input type="checkbox"/>
Mo. Day		

**CUSTOMER USE ONLY**

**PAYMENT BY ACCOUNT**

Express Mail Corporate Acct. No.

Federal Agency Acct. No. or  
Postal Service Acct. No.

**WAIVER OF SIGNATURE (Express Mail Only)**

I wish delivery to be made without obtaining signature of addressee or addressee's agent (if delivery employee judges that article can be left in secure location) and I authorize that delivery employee's signature constitutes valid proof of delivery.

**NO DELIVERY**

☐ Weekend ☐ Holiday

Maier Signature

FROM: (PLEASE PRINT)

PHONE (858) 314-1200

JONES DAY  
12205 EL CAMINO REAL #260  
SAN DIEGO, CA 92130

TO: (PLEASE PRINT)

PHONE ( )

COMMISSIONER FOR PATENTS  
P.O. Box 1450  
ALEXANDRIA, VA

ZIP + 4 (U.S. ADDRESSES ONLY. DO NOT USE FOR FOREIGN POSTAL CODES.)

22313 + 1450

FOR INTERNATIONAL DESTINATIONS, WRITE COUNTRY NAME BELOW.

**FOR PICKUP OR TRACKING**

Visit [www.usps.com](http://www.usps.com)

Call 1-800-222-1811



MIDWAY WINDOWS

SAN DIEGO, California

921109998

0567760110 -0089

(800)275-8777

11/05/2007

06:44:08 PM

Sales Receipt

Product Description	Sale Qty	Unit Price	Final Price
ALEXANDRIA VA 22313			\$21.40
Zone-8 Express Mail			
PO-Add			
1 lb. 13.80 oz.			
Label #:			
2nd Day Noon / Normal			
Delivery			
Customer Postage			-\$21.40
Subtotal:			\$0.00
Total:			\$0.00

Total:

Paid by:

Order stamps at [usps.com/shop](http://usps.com/shop) or call 1-800-Stamp24. Go to [usps.com/clicknship](http://usps.com/clicknship) to print shipping labels with postage. For other information call 1-800-ASK-USPS.

Bill #: 1001103207483

Clerk: 36

All sales final on stamps and postage. Refunds for guaranteed services only. Thank you for your business.

\*\*\*\*\*  
HELP US SERVE YOU BETTER  
\*\*\*\*\*

Go to: <http://gx.gallup.com/pos>

TELL US ABOUT YOUR RECENT POSTAL EXPERIENCE

YOUR OPINION COUNTS

\*\*\*\*\*


Customer Copy

U.S. POSTAL SERVICE **CERTIFICATE OF MAILING**  
MAY BE USED FOR DOMESTIC AND INTERNATIONAL MAIL. DOES NOT  
PROVIDE FOR INSURANCE-POSTMASTER'S RISK

Received From:  
JONES DAY  
12205 EL CAMINO REAL #20  
SAN DIEGO, CALIF 92130

One piece of ordinary mail addressed to:  
COMMISSIONER FOR PATENTS  
P.O. Box 1450  
ALEXANDRIA, VA 22313-1450

PS Form 3817, January 2001



**Express Mail No.:** EB 132603053 US

**Date Mailed:** November 5, 2007

**Application No.:** 10/720.134

**Filed:** November 25, 2003

**Application of:** Jerussi *et al.*

**For:** DERIVATIVES OF VENLAFAXINE AND METHODS OF PREPARING AND USING THE SAME

1. Response Pursuant to 37 C.F.R. § 1.111 (6 pages) with copy of cited United States Patent No. 6,673,838 B2 (32 pages); and
2. Petition for Extension of Time (one month) (1 page, in duplicate).



**DOCKET:** 4821-531-999  
**CAM:** 208423-999528

**Sender:** Hoon Choi/Ltd Recog. No. L0209  
**For:** Anthony M. Insogna/Reg. No. 35,203